


# **The Use of New Molecular Genetic Technologies in Reproductive Medicine**

*Jürgen Neesen  
Institute of Medical Genetics  
Medical University of Vienna*

# Landmarks of Molecular Genetic Technologies



**How can new molecular genetic technologies help an infertile couple to get a healthy baby?**


# Chromosome anomalies are a main reason for pregnancy losses

approximately 0.6% of all newborn have a chromosome anomaly


10%–15% of clinically recognized pregnancies end with a first trimester loss

using assisted reproductive technologies (ART) miscarriage rates of 36-69% were reported and in up to 83% of miscarriages aneuploidy was detected

Nayak et al, 2011




**Chromosome aneuploidies contribute to the vast majority of pregnancy losses in both natural as well as ART conceptions**



**Solution of this problem:**

**Identification of embryos without a chromosome anomalies**

# Origin of non disjunction in human




## division errors for chromosome 21

maternal origin ~ 90 %  
paternal origin 5-8%

MI error: 69% MII error: 22%  
MI error: 2% MII error: 3%

mitotic origin ~ 5%

# Fluorescence in situ Hybridisation (FISH)



The image on the left shows the result after the first round of FISH using probes for chromosomes X (yellow), Y (aqua), 16 (green), and 21 (orange); and the one on the right shows the result after the second round of FISH using probes for chromosomes 13 (orange), 15 (yellow), 18 (aqua), and 22 (green). The blue is DAPI used as counterstaining.

<http://quizlet.com/14732443/molecular-diagnosis-onward-flash-cards/>

**using FISH technology only few chromosomes can be tested for aneuploidy**

# DATA from the Literature

Hum Reprod. 2008 (12):2813-7.


**No beneficial effect of preimplantation genetic screening in women of advanced maternal age with a high risk for embryonic aneuploidy.**

Twisk M, Mastenbroek S, Hoek A, Heineman MJ, van der Veen F, Bossuyt PM, Reprint S, Korevaar JC.

In the PGS group, a single blastomere was aspirated from each embryo and analysed for aneuploidies using probes for chromosomes 1, 13, 16, 17, 18, 21, X and Y.

# Frequency of chromosome aneuploidies

polar bodies of 886 oocytes were analysed by array-CGH; 600 (68%) oocytes were aneuploid, meiotic separation errors of 6-18% were observed for all chromosomes



the need for new technologies allowing to analyse all chromosomes

- array-CGH technology
- real time or quantitative PCR
- NGS

# Single Nucleotide Polymorphism (SNP)


a single nucleotide alteration in genomic DNA found in > 1% of the population (<1% it is called variation)

SNPs are found every 100-300 bps of the genome

accounts for ~ 90% of genomic variation


2/3 SNPs are C – T

SNPs are evolutionarily stable



# Oligonucleotide and SNP

human metaphase



exon 4 of NSD1 gene

chromosome 5 (only forward strand is shown)

TTTCCAACCGGAGGCC **C** TATCGGCAGTACTA CGT  
GGAGGCTTTTGGAGATCCTTCTGAGAGAGCCT GGG  
TGGCTGGAAAAGCAAT CGTC ATGTTTGAAGGCAGA  
CAT CA ATT CG AAGAGCTACCTGTCCTTAGGAGAAG  
AGGGAAACAGAAAGAAAAAGGATATAGGCATAAG


TTTCCAACCGGAGGCC **T** TATCGGCAGTACTA CGT  
GGAGGCTTTTGGAGATCCTTCTGAGAGAGCCT GGG  
TGGCTGGAAAAGCAAT CGTC ATGTTTGAAGGCAGA  
CAT CA ATT CG AAGAGCTACCTGTCCTTAGGAGAAG  
AGGGAAACAGAAAGAAAAAGGATATAGGCATAAG

**rs148455858 SNP**

Alleles **C/T** | Ancestral: **C**

Location Chromosome **5: 177204136**  
(forward strand)

# Microarray - Oligonucleotide/SNP-Array




Microarray is a dual color array containing 60-mer oligonucleotide


4x 180K chip  
169,991 unique probes  
110,712 (CGH) + 59,647 (SNP)



CytoScan 750K Array  
750 000 markers  
550 000 unique non-polymorphic probes  
200 000 SNPs



# The process of array-CGH



Agilent      500 – 1000 ng DNA  
handling time ~ 1 day  
hybridization ~ 24 hours  
scanning and analysis 2-4 hours

Affimetrix    250 – 500 ng DNA  
handling time ~ 1- 2 days  
hybridization ~ 24 hours  
scanning and analysis 2-4 hours

# Microarray - Oligonucleotide/SNP-Array

The oligonucleotide /SNP array can detect with high sensitivity gains and losses of DNA (by detecting large stretches of SNPs homozygosity).

Regions of SNP homozygosity indicate:


1. chromosomal deletion
2. a possible consanguinity of the parents
3. uniparental isodisomy (complete or partial)

The SNP array test does not detect all changes of the chromosomes. In particular, it is not able to find structural rearrangements of the chromosomes and it cannot detect small changes in the DNA (point mutations, deletion or duplications of few nucleotides)

# array-CGH analysis in PID




1 ml blood (several million white blood cells)  
→ 100 µg DNA (no amplification step necessary)



polar body biopsy



blastomer biopsy



trophoblast biopsy



**Whole Genome Amplification (time: 3h)**





DNA:  
few picogram

DNA:  
5-10 microgram

# array-CGH analysis in PID

complete time after biopsy 10-23h




DNA labelling ( time: 3h)  
200-400 ng DNA

hybridisation (3.5-16.5h)

analysis (30min)

# array-CGH analysis using DNA from polar bodies



# Comprehensive Chromosome Screening is highly predictive of clinical success

blinded nonselective study

48.2% of euploid blastocytes resulting in ongoing implantation per transfer




93.5% of aneuploid predicted blastocysts failed to implant

29.2% of euploid blastomere resulting in ongoing implantation per transfer

98.1% of aneuploid predicted blastomere failed to implant


Scott et al., 2012, Fertil Steril. 97(4):870-5

# PCR – quantitative PCR




# PCR – quantitative PCR

## 1. Denaturation Step




## 2. Annealing Step



## 3. Extension Step



if you start your PCR with more DNA, the fluorescence signal is detectable after less cycles



# NGS machines



Lifetech „Proton“

Chip PI  
output up to 10 Gb  
200bp  
reads 60-80 millions  
time 4hr



NextSeq™ 500

High Output Flow Cell  
output 100 Gb / 2x 150bp  
reads 400 millions / time 29hr



Lifetech „PGM“

Chip 316  
output 300-600 Mb / 200bp  
reads 2-3 millions / time 3hr



Illumina „MiSeq“

Kit v3  
output 3.5 Gb  
2x 75bp  
reads 20 millions  
time 21hr

# Coverage / Amount of Data




			10X coverage	100x coverage
whole genome		<b>Genome:</b>		
	DNA extraction and fragmentation	~ 3-6 GB	30 GB	300 GB
exome		<b>Exome:</b>		
	exons are amplified by PCR or enriched using cDNA (~25 000 genes)	~ 30-50 MB	500 MB	5GB
targeted sequencing		<b>200 Gene</b>		
	targeted sequences are amplified by PCR (thousands of amplicons)	~ 400 kb	4 MB	40 MB



# NGS-next generation sequencing

Using „Barcodes“ (2 - 96x probes) it is possible to analyse DNA probes of several patients in one run → lower costs

CGGATTACCATGTG 1  
 ↓  
 CGGATGACCATGTG 2



Each sequence fragment is bioinformatically aligned to the genome, and potential sequence variants identified. Here we see a possible heterozygous A>T single nucleotide polymorphism

# Fields of application of NGS in reproductive medicine

- panel sequencing: increased nuchal translucency (NT), cardiac anomalies and a normal karyotype indication for Noonan syndrome (PTPN11, KRAS, RAF1, BRAF and MAP2K1 )
- targeted sequencing: screening of infertile couples for mutations frequently found in the population (cystic fibrosis, sickle cell disorder, hemophilia, hot spot mutations)
- aneuploidy screening: screening of polar bodies, blastomers or trophoblasts for aneuploidy  
Wells et al., 2014, J Med Genet. Aug;51(8):553-62.  
*Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation.*
- NIPT fetal cell free DNA found in the plasma of the pregnant mother can be isolated and analysed

# Outlook

NIPT /NGS

non invasive methods will strongly increase  
if costs for the test decrease, more women will use NIPT  
aneuploidy screening

it is already possible to analyse the whole genome of a fetus  
using cell free DNA; therefore, also monogenetic disorders will  
be analysed by NIPT in future

infertile couples

trophectoderm cells will be routinely screened for chromosome  
anomalies using array CGH or NGS technology; more genetic  
markers should be identified that are involved in the process of  
implantation and they may be tested in order to increase the  
pregnancy rate (mtDNA)

**➔ genetic analyses will play a very relevant role in  
reproductive medicine**